Evidence map›Paper›PMID 28702855›Full record

ReviewMycopathologia2018

N-Chlorotaurine, a Promising Future Candidate for Topical Therapy of Fungal Infections.

Markus Nagl, Roland Arnitz, Michaela Lackner

Open access · hybridAbstract readReview
In one paragraph

Review in Mycopathologia, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.

0numbers the graph read from it
0cells of the map it votes in
18citing papers in PubMed
1.3field-weighted citation impact, top 22% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

18 citing papers in PubMed, 34 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Efficacy of Inhaled N-Chlorotaurine in a Mouse Model ofJournal of fungi (Basel, Switzerland) · 2022
    Article
  10. Article
  11. Metabolites · 2022
    Article
  12. Review
  13. Review
  14. Article
  15. Activity ofAntibiotics (Basel, Switzerland) · 2021
    Article
  16. Article
  17. Review
  18. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Markus NaglDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstr. 41, 1st Floor, 6020, Innsbruck, Austria. m.nagl@i-med.ac.at.
Roland ArnitzDepartment of Pneumology, District Hospital Vöcklabruck, Vöcklabruck, Austria.
Michaela LacknerDivision of Hygiene and Medical Microbiology, Medical University of Innsbruck, Schöpfstr. 41, 1st Floor, 6020, Innsbruck, Austria.
Universität Innsbruck · AT

Funding

Austrian Science Fund grant no. KLI459-B30Austrian Science Fund FWF KLI 459
6 · The paper itself

Abstract

N-Chlorotaurine (NCT) is a mild long-lived oxidant that can be applied to sensitive body regions as an endogenous antiseptic. Enhancement of its microbicidal activity in the presence of proteinaceous material because of transchlorination, a postantibiotic/postantifungal effect and antitoxic activity renders it interesting for treatment of fungal infections, too. This is confirmed by first case applications in skin and mucous membranes of different body sites. Recent findings of good tolerability of inhaled NCT suggest further investigations of this substance for treatment of bronchopulmonary diseases, where microorganisms play a role, particularly multi-resistant ones. The availability of a well-tolerated and effective inhaled antiseptic with anti-inflammatory properties could be a significant progress, in particular for chronic pulmonary diseases, such as chronic obstructive pulmonary disease or cystic fibrosis.

Indexed as

Administration, InhalationAdministration, TopicalAnimalsAnti-Infective Agents, LocalHumansMycosesTaurineAnti-Infective Agents, LocalN-chlorotaurineTaurineAntisepticCOPDCystic fibrosisFungiInhalationN-chlorotaurine

Identifiers

PMID28702855
PMCPMC5773618
OpenAlexW2734625286

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.